Study guide
12.4 Cardiovascular Pharmacotherapy: Nitroglycerin, ASA & Epinephrine
COPR Primary Care Paramedic PCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The COPR PCP Exam & How to Use This Guide
0.1 About the COPR PCP Entry-to-Practice Examination 0.2 The 2024 CPCF Blueprint: Competence Areas, Weights & Question Targets 0.3 Eligibility, Attempts, Accommodations & a 12-Week Study Plan
2 Chapter 1: Professionalism, Ethics & Legal Framework
1.1 Ethical Practice, Professionalism & Values in Canadian Paramedicine 1.2 Professional Accountability, Candour & Duty to Report 1.3 Regulatory Framework, Scope of Practice & Informed Consent
3 Chapter 2: Patient-Centred Communication & Clinical Documentation
2.1 Therapeutic Communication, Empathy & De-escalation 2.2 Patient-Centred Interviewing & Comprehensive History Gathering 2.3 Clinical Information Sharing, Consent & Incident Disclosure 2.4 Clinical Documentation, Electronic Health Records & Privacy 2.5 Shared Decision-Making, Health Literacy & Engaging Patients in Care Plans
4 Chapter 3: Interprofessional Collaboration & Continuum of Care
3.1 Care Team Roles, Task Delegation & Shared Decision-Making 3.2 Scene Collaboration, Interagency Conflict & Safety Culture 3.3 Safe Transfer of Care, Clinical Handover & Transition Plans
5 Chapter 4: Evidence-Informed Practice & Continuing Competence
4.1 Clinical Mentorship, Role Modelling & Reflective Debriefing 4.2 Evidence-Informed Practice, Guideline Translation & Lifelong Learning 4.3 Continuing Competence, Personal Learning Plans & Adapting to a Changing Profession
6 Chapter 5: Professional Health, Safety & Operational Resilience
5.1 Paramedic Wellness, Occupational Stress Injuries & PTSI Recognition 5.2 Fitness for Duty, Ergonomics, Safe Lifting & Peer Support Systems 5.3 Monitoring Personal Health, Healthy Coping & Removing Yourself from Practice
7 Chapter 6: Health Advocacy, Equity & Culturally Safe Care
6.1 Social Determinants of Health, Cultural Safety & Anti-Oppressive Practice 6.2 Anti-Indigenous Racism, Truth and Reconciliation & Trauma-Informed Care 6.3 System-Level Advocacy, Social Accountability & Working Toward Reconciliation
8 Chapter 7: Situational Leadership & Scene Operations
7.1 Prehospital Scene Assessment, Initial Incident Command & Hazard Mitigation 7.2 Clinical Resource Coordination & Practice Improvement Systems
9 Chapter 8: Infection Prevention, Diagnostics & Scene Preparedness
8.1 Infection Prevention and Control: Routine Practices, PPE & Sharps Safety 8.2 Point-of-Care Risk Assessment & Mass Casualty/CBRNE Principles 8.3 Paramedic Scope along the Continuum & Diagnostic Laboratory Correlation 8.4 Point-of-Care Risk Assessment, Situational Awareness & Securing Additional Resources
10 Chapter 9: Patient Assessment, Physical Examination & Vital Signs
9.1 Primary Survey, Rapid Trauma/Medical Exam & Threat Identification 9.2 Secondary Assessment, History Integration (SAMPLE/OPQRST) & Lifespan Adaptation 9.3 Vital Signs Interpretation, Glasgow Coma Scale & Clinical Reassessment
11 Chapter 10: Diagnostic Monitoring: ECG & Capnography
10.1 Prehospital Pulse Oximetry, Glucometry & Urinalysis 10.2 Prehospital Electrocardiography: 3-Lead Monitoring & 12-Lead Acquisition 10.3 Continuous Waveform Capnography (EtCO2) & Ventilation Dynamics
12 Chapter 11: Airway Management & Ventilation Therapeutics
11.1 Basic Airway Maneuvers, Positioning, OPA/NPA & Suctioning Techniques 11.2 Supraglottic Airway (SGA) Devices & Tracheostomy Management 11.3 Oxygen Delivery Modalities, Regulators & Safety 11.4 Positive Pressure Ventilation, BVM Mechanics, PEEP & CPAP 11.5 Foreign Body Airway Obstruction: Recognition & Relief Across the Lifespan 11.6 Beyond CPAP: BiPAP, High-Flow Nasal Cannula Therapy & Choosing a Ventilation Strategy
13 Chapter 12: Cardiovascular Emergencies & Resuscitative Care
12.1 High-Performance Cardiopulmonary Resuscitation (CPR) & Automated/Manual Defibrillation 12.2 Acute Coronary Syndromes (ACS), STEMI Recognition & Pathophysiology 12.3 Heart Failure, Cardiogenic Shock & Left Ventricular Assist Devices (LVAD) 12.4 Cardiovascular Pharmacotherapy: Nitroglycerin, ASA & Epinephrine
14 Chapter 13: Trauma Emergencies, Hemorrhage Control & SMR
13.1 External Hemorrhage Control: Tourniquets, Wound Packing & Pelvic Binders 13.2 Spinal Motion Restriction (SMR) & Canadian C-Spine Rule Application 13.3 Thoracic & Abdominal Trauma Management 13.4 Musculoskeletal Trauma, Fractures, Splinting & Dislocation Reduction 13.5 Head Injury & Traumatic Brain Injury: Preventing Secondary Brain Injury 13.6 Burns and Soft-Tissue Injury: Thermal, Chemical, Electrical & Inhalation
15 Chapter 14: Medical, Endocrine, Toxicological & Environmental Emergencies
14.1 Acute Respiratory Distress: Asthma, COPD, Pulmonary Edema & Anaphylaxis 14.2 Neurological Emergencies: Stroke Syndromes, TIA, Seizures & Status Epilepticus 14.3 Endocrine Emergencies: Hypoglycemia, DKA/HHS & Glucagon/Dextrose Administration 14.4 Toxicological Emergencies, Opioid Toxicity, Naloxone & Environmental Exposure 14.5 Abdominal, Gastrointestinal & Hepatobiliary Emergencies 14.6 Genitourinary, Renal & Dialysis Emergencies 14.7 Haematologic, Immunologic, EENT & Dental Emergencies
16 Chapter 15: Special Populations: Obstetrics & Neonatal Resuscitation
15.1 Antepartum Emergencies, Preeclampsia & Normal Spontaneous Childbirth 15.2 Complicated Deliveries: Breech, Prolapsed Cord, Nuchal Cord & Postpartum Hemorrhage 15.3 Neonatal Resuscitation Program (NRP) in the Prehospital Setting
17 Chapter 16: Special Populations: Pediatrics, Geriatrics, Palliative & Vulnerable Patients
16.1 Pediatric Assessment Triangle (PAT), Common Emergencies & Pediatric Dosing 16.2 Geriatric Syndromes, Polypharmacy, Elder Vulnerability & Falls 16.3 Palliative Emergencies, Medical Assistance in Dying (MAID) & Community Paramedicine 16.4 Bariatric Patients, Limited Mobility & Patients With Different Abilities
18 Chapter 17: Clinical Foundations — Terminology, Anatomy, Physiology & Pathophysiology
17.1 Medical & Paramedic Terminology, Abbreviations and Anatomical Reference 17.2 Applied Anatomy & Physiology Across Body Systems and the Lifespan 17.3 Core Pathophysiology: Cellular Injury, Hypoperfusion & the Shock States
19 Chapter 18: Pharmacology & Safe Medication Administration
18.1 Pharmacology Foundations: Classification, Pharmacokinetics & Pharmacodynamics 18.2 Safe Medication Administration: The Rights, Dose Calculation & Error Management 18.3 Medication Routes: Enteral, Parenteral, Inhaled & Topical Administration
20 Chapter 19: Vascular Access, Fluid Therapy, Routine Care & Patient Movement
19.1 Peripheral IV Cannulation, Venipuncture, Saline Locks & Maintaining Infusions 19.2 Intraosseous Access, Crystalloid Fluid Therapy, Pressure Infusers & Blood Products 19.3 Routine Care: Urinary Catheters, Ostomy & Drainage Systems, Chest Tubes & Wound Care 19.4 Patient Handling, Movement, Positioning & Transfer to a Higher Level of Care
21 Chapter 20: Mental Health, Behavioural Emergencies & Substance Use
20.1 Mental Status Assessment, Cognition & Capacity to Consent 20.2 Behavioural Emergencies, Severe Agitation & Safe Restraint 20.3 Substance Use, Addictions, Withdrawal & Harm Reduction
12.4 Cardiovascular Pharmacotherapy: Nitroglycerin, ASA & Epinephrine
Key Takeaways Explain This Topic AI
Acetylsalicylic acid (ASA, 160–325 mg chewed) irreversibly acetylates and inhibits cyclooxygenase-1 (COX-1), blocking thromboxane A2 (TXA2) synthesis to prevent further platelet aggregation and thrombus propagation in acute coronary syndromes.
Sublingual nitroglycerin (0.4 mg spray/tablet every 5 min up to 3 doses) is converted into nitric oxide (NO), stimulating cGMP production to cause potent systemic venodilation, which lowers left ventricular preload and myocardial wall tension.
Prehospital nitroglycerin contraindications include: SBP <90–100 mmHg, heart rate <50 bpm or >100 bpm, right ventricular infarction (ST elevation in V4R), and recent phosphodiesterase type 5 (PDE-5) inhibitor use (sildenafil/vardenafil within 24 hours, tadalafil within 48 hours).
Epinephrine in adult cardiac arrest is administered at 1 mg (1:10,000 / 0.1 mg/mL) IV/IO every 3–5 minutes; its primary benefit is alpha-1-mediated peripheral vasoconstriction that increases systemic vascular resistance and elevates coronary perfusion pressure (CPP).
Epinephrine in severe anaphylactic shock is dosed at 0.3–0.5 mg (1:1,000 / 1 mg/mL) administered strictly Intramuscularly (IM) into the anterolateral mid-thigh (vastus lateralis) for rapid systemic absorption.
Last updated: September 2026
- 12.4 Cardiovascular Pharmacotherapy: Nitroglycerin, ASA & Epinephrine
- Pharmacological Foundations: Adrenergic, Nitrate & Antiplatelet Pathways
Primary care paramedics routinely administer targeted cardiovascular pharmacotherapy to alter intravascular hemodynamics, inhibit thrombogenesis, and stimulate adrenergic receptor pathways (CPCF Appendix A #5, #32). Mastering the receptor kinetics, cellular mechanisms, contraindications, and potential toxicities of Acetylsalicylic Acid (ASA) , Nitroglycerin , and Epinephrine is essential for clinical competence and paramedic licensure in Canada.
Acetylsalicylic Acid (ASA): Mechanism, Antiplatelet Kinetics & Dosing
Acetylsalicylic acid (aspirin) is an irreversible antiplatelet agent that forms the absolute cornerstone of early medical management in suspected Acute Coronary Syndrome (ACS).
Cellular Mechanism of Action
Platelet activation at the site of a ruptured atheromatous plaque generates arachidonic acid from platelet membrane phospholipids via phospholipase A2. Intracellular cyclooxygenase-1 (COX-1) converts arachidonic acid into prostaglandin H2 ( P G H 2 PGH_2 PG H 2 ), which is subsequently isomerized by thromboxane synthase into Thromboxane A2 (TXA2) . TXA2 is a potent platelet agonist and vasoconstrictor that promotes platelet degranulation, shape change, and activation of glycoprotein IIb/IIIa receptors, driving rapid thrombus propagation.
Irreversible Acetylation: ASA covalently acetylates a serine residue (Ser-529) in the active catalytic channel of platelet COX-1, permanently blocking substrate access. Because platelets are anucleate cell fragments lacking ribosomal machinery, they cannot synthesize replacement COX-1 proteins. Platelet COX-1 remains inactivated for the entire circulating lifespan of the platelet (7 to 10 days) .
Clinical Dosing & Administration: 160 mg to 325 mg (in Canada, standard prehospital administration is two 80 mg or 81 mg chewable pediatric tablets = 160–162 mg ).
Chewable Formulation: Tablets must be chewed thoroughly before swallowing. Chewing pulverizes the formulation and enables rapid direct absorption across the rich vascular network of the buccal and sublingual mucosa, achieving therapeutic antiplatelet action within 15 to 20 minutes . Swallowing enteric-coated whole tablets delays therapeutic onset for up to 2 to 4 hours due to slow gastric emptying.
Indications & Strict Contraindications
Indications: All patients with suspected ischemic chest pain or anginal equivalents suggestive of Acute Coronary Syndrome.
Absolute Contraindications:
True anaphylactic hypersensitivity to ASA, salicylates, or non-steroidal anti-inflammatory drugs (NSAIDs) (manifesting as bronchospasm, urticaria, or angioedema).
Active, gross gastrointestinal hemorrhage (e.g., active hematemesis, melena) or severe acute bleeding diathesis.
Clarifying Daily Aspirin Regimens: A patient who takes daily baby aspirin (81 mg) has partial platelet suppression. Paramedics must administer the full prehospital loading dose (160–162 mg chewable) to ensure complete blockade of all newly released circulating platelets.
Sublingual Nitroglycerin: Hemodynamics, Preload Reduction & Administration
Nitroglycerin (glyceryl trinitrate [GTN]) is an organic nitrate that acts as a potent vascular smooth muscle relaxant and vasodilator.
Mechanism of Action & Intracellular Cascade
Conversion to Nitric Oxide: Nitroglycerin enters vascular endothelial and smooth muscle cells, where it is bio-transformed by mitochondrial aldehyde dehydrogenase-2 (ALDH-2) into active nitric oxide (NO) .
Activation of Guanylyl Cyclase: Nitric oxide stimulates soluble guanylyl cyclase (sGC), which catalyzes the intracellular conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP) .
Dephosphorylation of Myosin: Elevated cGMP activates protein kinase G (PKG), which promotes intracellular calcium extrusion and dephosphorylates myosin light chains, inducing profound vascular smooth muscle relaxation .
Hemodynamic Effects
Venodilation (Predominant Effect): At standard prehospital sublingual doses, nitroglycerin acts primarily as a venodilator . It dramatically expands capacitance in the systemic venous system, pooling blood in peripheral and splanchnic vascular beds. This reduces venous return to the right heart, lowering Left Ventricular End-Diastolic Pressure ( preload ) and reducing left ventricular wall tension. By Laplace's law ( T = P × r / 2 h T = P \times r / 2h T = P × r /2 h ), diminished wall tension directly curtails myocardial oxygen demand ( M V O 2 MVO_2 M V O 2 ).
Coronary Vasodilation: Relieves dynamic coronary vasospasm, improves collateral coronary perfusion, and redistributes blood flow toward ischemic subendocardial layers.
Arteriolar Dilation (Higher Doses): Produces modest reduction in systemic vascular resistance, decreasing left ventricular afterload .
Clinical Administration Parameters
Formulation: 0.4 mg (400 mcg) per metered sublingual spray or sublingual tablet.
Frequency: 1 dose every 5 minutes, up to a maximum of 3 doses, provided vital signs remain within safe parameters.
Mandatory Reassessment: Paramedics must reassess blood pressure and heart rate immediately before each dose.
Nitroglycerin Contraindications: PDE-5 Inhibitors & Right Ventricular Infarction
Nitroglycerin is a potent vasoactive medication with strict physiological and pharmacological contraindications: Absolute Contraindications to Prehospital Nitroglycerin:
- 1. Systolic Blood Pressure <90–100 mmHg (or >30 mmHg drop below baseline)
- 2. Heart rate outside the range set by the local medical directive
- (commonly bradycardia below 50-60 bpm or tachycardia above 100-160 bpm;
- Canadian provincial directives differ, so know your own)
- 3. Right Ventricular Myocardial Infarction (ST elevation in lead V4R)
4. Recent Use of Phosphodiesterase Type 5 (PDE-5) Inhibitors:
- Sildenafil (Viagra, Revatio) within 24 hours
- Vardenafil (Levitra) within 24 hours
- Tadalafil (Cialis, Adcirca) within 48 hours
- The Lethal PDE-5 Inhibitor Interaction
Phosphodiesterase type 5 (PDE-5) is the primary intracellular enzyme responsible for breaking down cGMP into inactive 5'-GMP. Medications such as sildenafil, vardenafil, and tadalafil are competitive PDE-5 inhibitors prescribed for erectile dysfunction and pulmonary arterial hypertension:
Synergistic cGMP Accumulation: Nitroglycerin dramatically increases cGMP synthesis, while PDE-5 inhibitors simultaneously block cGMP breakdown. When co-administered, cGMP concentrations inside vascular smooth muscle skyrocket to massive levels.
Refractory Hemodynamic Collapse: This triggers uninhibited, systemic arteriolar and venular vasodilation. Systemic vascular resistance drops precipitously, producing severe, irreversible hypotension, complete loss of coronary perfusion pressure, and fatal cardiovascular collapse refractory to aggressive fluid resuscitation.
Time Windows: Sildenafil and vardenafil possess elimination half-lives of approximately 4 hours, establishing an absolute contraindication window of 24 hours . Tadalafil has an extended elimination half-life (~17.5 hours), dictating an absolute contraindication window of at least 48 hours .
Epinephrine in Cardiac Arrest: Alpha-1 Vasoconstriction & Perfusion Pressures
Epinephrine (adrenaline) is an endogenous catecholamine that non-selectively stimulates alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors. In cardiac arrest resuscitation, it serves as the primary vasopressor.
Mechanism of Action in Pulseless Arrest
During cardiopulmonary resuscitation, forward blood flow is minimal (~20%–30% of baseline). The therapeutic objective of epinephrine in cardiac arrest is NOT cardiac stimulation (beta-1 agonism), but rather potent peripheral vasoconstriction mediated by alpha-1 adrenergic receptors :
Alpha-1 Peripheral Vasoconstriction: Epinephrine binds alpha-1 receptors on vascular smooth muscle, activating the Gq-phospholipase C pathway to increase intracellular calcium. This intensely constricts non-essential peripheral arterial beds (skin, skeletal muscle, splanchnic circulation, renal vasculature).
Elevating Aortic Diastolic Pressure: Massive peripheral vasoconstriction prevents blood runoff into distal capillary beds, elevating aortic root diastolic pressure during the decompression phase of CPR.
Augmenting Coronary & Cerebral Perfusion: As aortic diastolic pressure rises, the pressure gradient driving blood flow into the coronary arteries ( Coronary Perfusion Pressure [CPP] ) and cerebral circulation increases significantly, promoting myocardial recovery and the return of organized electrical activity.
Clinical Administration in Adult Resuscitation
Formulation & Concentration: 1 mg of 1:10,000 (0.1 mg/mL) administered intravenously (IV) or intraosseously (IO).
Flush Protocol: Follow each 1 mg dose with an immediate 20 mL normal saline flush and elevate the patient's extremity for 10 to 20 seconds to rapidly propel the medication from peripheral veins into the central circulation.
Timing & Rhythms:
Non-Shockable Rhythms (Asystole / PEA): Administer as soon as vascular access is established . Early epinephrine administration in non-shockable arrest correlates strongly with higher ROSC rates.
Shockable Rhythms (VF / pulseless VT): Administer after the second shock (during the 3rd CPR cycle), repeated every 3 to 5 minutes thereafter. Initial efforts in shockable rhythms prioritize immediate defibrillation and CPR before pharmacotherapy.
Epinephrine in Severe Anaphylaxis: Intramuscular Mechanics & Route Safety
In severe acute anaphylaxis, massive systemic mast cell and basophil degranulation releases histamine, leukotrienes, and platelet-activating factor, triggering catastrophic bronchospasm, mucosal angioedema, and distributive shock.
Receptor Mechanics in Anaphylaxis
Alpha-1 Agonism: Reverses profound peripheral vasodilation, restores systemic vascular resistance, and curtails microvascular capillary leakage, relieving life-threatening laryngeal angioedema.
Beta-2 Agonism: Relaxes bronchial smooth muscle via adenylate cyclase stimulation (increasing cyclic AMP), reversing acute bronchospasm; simultaneously binds beta-2 receptors on mast cells, halting further release of inflammatory mediators.
Beta-1 Agonism: Enhances cardiac inotropy and chronotropy to support cardiac output in distributive shock.
Dosing & Administration: The Anterolateral Thigh (Vastus Lateralis)
Concentration: 1:1,000 (1.0 mg/mL) .
Adult Dose: 0.3 mg to 0.5 mg (0.3–0.5 mL of 1:1,000) administered strictly Intramuscularly (IM) .
Pediatric Dose: 0.01 mg/kg IM (maximum single dose 0.3 mg).
Anatomical Site: The anterolateral mid-thigh (vastus lateralis) is the mandatory injection site. Pharmacokinetic studies prove that the extensive vascularity of the vastus lateralis achieves peak plasma epinephrine concentrations within 8 minutes —more than three times faster than injection into the deltoid muscle or subcutaneous adipose tissue.
Caution
The Lethal Error of IV 1:1,000 Epinephrine: Administering the concentrated 1:1,000 (1 mg/mL) formulation intravenously to a non-arrest patient is a lethal medication error. A rapid IV bolus of concentrated epinephrine triggers extreme hypertension, intracranial hemorrhage, acute myocardial infarction, and fatal ventricular tachyarrhythmias. IV epinephrine is reserved strictly for cardiac arrest (using the dilute 1:10,000 formulation) or highly specialized, micro-dose IV infusions titrated by advanced life support clinicians.
Comprehensive Cardiovascular Pharmacotherapy Comparison
Medication Clinical Formulation & Route Primary Mechanism of Action Main Prehospital Indication Standard Prehospital Adult Dose Critical Contraindications
Acetylsalicylic Acid (ASA) Oral chewable tablets (80 mg / 81 mg). Irreversible inhibition of platelet COX-1; blocks TXA2 synthesis. Suspected Acute Coronary Syndrome (ACS). 160 mg to 325 mg chewed (typically 160–162 mg). True salicylate anaphylaxis; active, gross gastrointestinal hemorrhage.
Nitroglycerin (GTN) Sublingual metered spray or tablet (0.4 mg/dose). Organic nitrate; converts to NO, elevates cGMP, causes systemic venodilation (reduces preload). Ischemic chest pain (ACS); hypertensive acute pulmonary edema. 0.4 mg SL every 5 min (max 3 standard doses). SBP <90–100 mmHg; heart rate outside the range set by the local directive; RV infarction (V4R+); PDE-5 inhibitor use (24–48 h).
Epinephrine (Cardiac Arrest) Parenteral solution 1:10,000 (0.1 mg/mL) IV/IO. Alpha-1 vasoconstriction elevating aortic diastolic pressure and coronary perfusion pressure (CPP). Ventricular Fibrillation, pulseless VT, Asystole, PEA. 1.0 mg IV/IO every 3 to 5 minutes (with 20 mL flush). None in cardiac arrest (no absolute contraindications in pulseless arrest).
Epinephrine (Anaphylaxis) Parenteral solution 1:1,000 (1.0 mg/mL) IM. Alpha-1 vasoconstriction (reduces mucosal edema); Beta-2 bronchodilation and mast cell stabilization. Severe systemic anaphylactic shock; acute upper airway angioedema. 0.3 mg to 0.5 mg IM into anterolateral mid-thigh. No absolute contraindications in life-threatening anaphylaxis; never administer 1:1,000 IV bolus .
Clinical Scenario: ACS with a Hidden PDE-5 Inhibitor Interaction
A 58-year-old male calls 911 for sudden, crushing retrosternal chest pain radiating to both shoulders, accompanied by nausea and diaphoresis, which started 1 hour ago while gardening. Vital signs: BP 142/88 mmHg, HR 78 bpm regular, RR 18/min, SpO2 98% on room air.
Diagnostic Assessment: Paramedics obtain a 12-lead ECG within 7 minutes, demonstrating 2 mm ST elevation in leads V2 through V5 (acute anterior STEMI). STEMI bypass protocol is activated.
Pharmacological Screening: The crew prepares to administer standard ACS medications. When asked about medication allergies and current prescriptions, the patient initially denies taking any medications.
Targeted Medication Inquiry: Recognizing the severe risks of organic nitrates, the paramedic asks specifically: 'Have you taken any medications for erectile dysfunction, prostate issues, or pulmonary hypertension in the past two days, such as Viagra or Cialis?' The patient hesitates and admits to taking a tadalafil (Cialis) 20 mg tablet 32 hours ago .
Therapeutic Adjustment:
ASA: Paramedics immediately administer 162 mg of chewable ASA , which the patient chews and swallows. ASA has zero adverse hemodynamic interaction with PDE-5 inhibitors.
Nitroglycerin: The crew strictly withholds all nitroglycerin . Although 32 hours have passed, tadalafil's long elimination half-life mandates an absolute contraindication window of 48 hours. Administering nitroglycerin would precipitate catastrophic, fatal hypotension.
Pain Management: Alternative non-nitrate analgesia is coordinated with online medical direction, and the patient is transported without hemodynamic compromise directly to the catheterization laboratory.
Exam Pitfalls & High-Yield Pharmacotherapy Pearls
Withholding ASA for Daily Baby Aspirin Users: Never withhold prehospital chewable ASA because the patient takes 81 mg daily; provide the full 160–162 mg loading dose.
Missing Tadalafil's 48-Hour Window: Remembering that sildenafil is 24 hours but missing that tadalafil requires a full 48-hour washout is a frequent licensing exam trap.
Administering Nitroglycerin Outside the Permitted Heart-Rate Range: Nitroglycerin is withheld when the heart rate falls outside the range set by the local medical directive, because venodilation in an already tachycardic or bradycardic patient worsens myocardial ischemia. The exact cut-offs differ between Canadian provincial directives (commonly bradycardia below 50–60 bpm, tachycardia above 100–160 bpm), so answer the national principle on the examination and the local number on the road.
Route Errors with Epinephrine: Never administer 1:1,000 epinephrine via the intravenous route in anaphylaxis; it must be administered intramuscularly into the anterolateral thigh (vastus lateralis).